911P Case series of docetaxel, trastuzumab, and pertuzumab (DTP) and subsequent ado-trastuzumab emtansine (T-DM1) for recurrent or metastatic (R/M) HER2-positive salivary duct carcinoma (SDC)

Abstract

SDC is an aggressive subtype of salivary gland cancer. In R/M disease, androgen deprivation therapy (ADT) resulted in response rates (RR) of 18-53% in androgen receptor-positive SDC. SDCs are HER2-positive in 29-46% of cases and have shown RR of 70% on docetaxel and trastuzumab. Here, we present the results of HER2-positive SDC patients treated with DTP and subsequent T-DM1.